Reporting Net Loss, GSK Execs Tout Restructuring, Stay Mostly Mum on Avandia
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline's sales remained unchanged at £7 billion in the second quarter as legal and restructuring charges lead to a net loss.